VERAgene® comprehensive NIPT

Single test for aneuploidies, microdeletions and point mutations

ACCURATE | SAFE | RELIABLE

WHAT IS **VERAgene**?

- VERAgene is the **only non-invasive prenatal single screening test** that can simultaneously screen for aneuploidies, microdeletions and single gene diseases. During pregnancy, fetal cell-free DNA is released from the placenta and circulates in the mother's blood together with her own cell-free DNA.
- VERAgene needs a maternal blood sample during pregnancy, and a buccal swab sample from the biological father. Cell-free DNA is isolated from the mother's blood, and is analysed independently for fetal aneuploidies and microdeletions, and concurrently with the paternal DNA to detect potential genetic mutations in the parents.



WHAT DOES **VERAgene** TEST FOR?

AUTOSOMAL ANEUPLOIDIES: Down syndrome *(Trisomy 21),* **Edwards syndrome** *(Trisomy 18),* **Patau syndrome** *(Trisomy 13)*

SEX CHROMOSOME ANEUPLOIDIES: Turner syndrome *(Monosomy X),* **Triple X syndrome** *(Trisomy X),* **Klinefelter syndrome** *(XXY),* **Jacobs syndrome** *(XYY),* **XXYY syndrome**

MICRODELETIONS: DiGeorge syndrome *(22q11.2),* **1p36 deletion syndrome** *(1p36),* **Smith-Magenis syndrome** *(17p11.2),* **Wolf-Hirschhorn syndrome** *(4p16.3)*

MONOGENIC DISEASES: Panel of 100 autosomal recessive and X-linked monogenic diseases, including: **Cystic Fibrosis, Sickle-Cell disease, Beta Thalassemia**

For a complete list of the monogenic diseases screened by VERAgene please visit ***www.nipd.com***

** Gender determination can be done optionally.*

VERAgene® comprehensive NIPT	CONVENTIONAL SCREENING TESTS
CELL-FREE DNA extracted from maternal plasma	**SCREENING COMBINES...**
	BIOCHEMICAL SCREENING RESULTS; ULTRASOUND FINDINGS; OTHER PARAMETERS
HIGH ACCURACY > 99% detection rate for aneuploidies *Less pregnant women are being referred for diagnostic testing*	**LOW ACCURACY** 80-95% detection rate for aneuploidies *More pregnant women are being referred for diagnostic testing*
EARLY Screening for aneuploidies, microdeletions and monogenic diseases can be done from the 10th week of pregnancy	Screening for aneuploidies after the 12th week of pregnancy

WHY SHOULD I GET TESTED?

- VERAgene screens for many genetic conditions with no age-associated risk, biochemical or ultrasound markers. The cumulative risk for the fetus to be affected by one of the genetic conditions screened by VERAgene is approximately 1 in 50, based on high and moderate risk pregnancies.
- VERAgene can accurately screen for these conditions to help prospective parents take informed decisions about their pregnancies.

WHAT WILL THE REPORT TELL ME?

VERY HIGH RISK

Very high risk results indicate that there is an **increased possibility** of the fetus having at least one of the specified conditions

Require confirmation through a diagnostic test

VERY LOW RISK

Very low risk results indicate that there is a **very low possibility** of the fetus having one of the tested conditions

NIPD GENETICS A MEDICOVER COMPANY

NIPD Genetics Molecular Laboratories Ltd
www.nipd.com
info@nipd.com

MKT-PRE-VG-EPB-EN-V01